Study protocol for the Anesthesiology Control Tower—Feedback Alerts to Supplement Treatments (ACTFAST-3) trial: A pilot randomized controlled trial in intraoperative telemedicine [version 1; referees: 2 approved] by Gregory, Stephen et al.




Study protocol for the Anesthesiology Control
Tower—Feedback Alerts to Supplement
Treatments (ACTFAST-3) trial: A pilot
randomized controlled trial in intraoperative
telemedicine [version 1; referees: 2 approved]
Stephen Gregory
Washington University School of Medicine in St. Louis
Teresa M. Murray-Torres
Washington University School of Medicine in St. Louis
Bradley A. Fritz
Washington University School of Medicine in St. Louis
Arbi Ben Abdallah
Washington University School of Medicine in St. Louis
Daniel L. Helsten
Washington University School of Medicine in St. Louis
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Gregory, Stephen; Murray-Torres, Teresa M.; Fritz, Bradley A.; Ben Abdallah, Arbi; Helsten, Daniel L.; Wildes, Troy S.; Sharma,
Anshuman; Avidan, Michael S.; and ACTFAST Study Group, ,"Study protocol for the Anesthesiology Control Tower—Feedback
Alerts to Supplement Treatments (ACTFAST-3) trial: A pilot randomized controlled trial in intraoperative telemedicine [version 1;
referees: 2 approved]." F1000Research.7,. 623. (2018).
https://digitalcommons.wustl.edu/open_access_pubs/6962
See next page for additional authors
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs
Authors
Stephen Gregory, Teresa M. Murray-Torres, Bradley A. Fritz, Arbi Ben Abdallah, Daniel L. Helsten, Troy S.
Wildes, Anshuman Sharma, Michael S. Avidan, and ACTFAST Study Group





Study protocol for the Anesthesiology Control Tower—Feedback
Alerts to Supplement Treatments (ACTFAST-3) trial: a pilot
 randomized controlled trial in intraoperative telemedicine
[version 1; referees: 2 approved]
Stephen Gregory ,     Teresa M. Murray-Torres , Bradley A. Fritz ,


















































, UniversityChristian Ari Dalby Sørensen
of Copenhagen, Denmark
2
 22 May 2018,  :623 (doi:  )First published: 7 10.12688/f1000research.14897.1
 22 May 2018,  :623 (doi:  )Latest published: 7 10.12688/f1000research.14897.1
v1
Page 1 of 15
F1000Research 2018, 7:623 Last updated: 05 JUL 2018
  Michael S. Avidan ( )Corresponding author: avidanm@wustl.edu
  : Conceptualization, Funding Acquisition, Investigation, Methodology, Writing – Original Draft Preparation, Writing –Author roles: Gregory S
Review & Editing;  : Conceptualization, Funding Acquisition, Investigation, Methodology, Writing – Original Draft Preparation,Murray-Torres TM
Writing – Review & Editing;  : Conceptualization, Methodology, Writing – Review & Editing;  : Conceptualization, FormalFritz BA Ben Abdallah A
Analysis, Methodology, Writing – Review & Editing;  : Conceptualization, Funding Acquisition, Investigation, Writing – Review & Editing; Helsten DL




 Gregory S, Murray-Torres TM, Fritz BA   How to cite this article: et al. Study protocol for the Anesthesiology Control Tower—Feedback
Alerts to Supplement Treatments (ACTFAST-3) trial: a pilot randomized controlled trial in intraoperative telemedicine [version 1;
   2018,  :623 (doi:  )referees: 2 approved] F1000Research 7 10.12688/f1000research.14897.1





The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
 22 May 2018,  :623 (doi:  ) First published: 7 10.12688/f1000research.14897.1
Page 2 of 15
F1000Research 2018, 7:623 Last updated: 05 JUL 2018
Introduction
Each year, over 300 million surgical procedures are performed 
worldwide1. Unfortunately, many patients will experience sig-
nificant morbidity or mortality in the postoperative period2. 
Research conducted at our institution and others has dem-
onstrated an early postoperative mortality rate ranging from 
1–5% and 90-day to 1-year mortality rates between 5–10%2–13. 
Additionally, 10–40% of patients will experience some type 
of postoperative surgical complication, including surgical site 
infection, respiratory complications, myocardial infarction, 
stroke and acute kidney injury, resulting in a three- to seven-fold 
increase in postoperative mortality3,4,11,12.
Despite the overall decline in surgical morbidity and mortal-
ity over time, the risk of perioperative adverse events remains 
substantial2. Some of this risk may be a manifestation of either 
underlying patient pathology or the complexity of the surgi-
cal procedure itself9,12,14,15. However, evidence also suggests 
that medical errors contribute considerably to negative patient 
outcomes16,17. Although some errors may be considered active, 
such as the administration of an incorrect medication, the fail-
ure to follow established clinical practice guidelines and recom-
mendations likely has a more significant overall detrimental 
effect on patient outcomes. Prior studies have documented that 
deviation from evidence-based standards of care is common, 
and that this deviation results in poorer patient outcomes18–22.
Interventions to improve patient safety and outcomes remain 
a major focus in anesthesiology. The complexity of anesthetic 
practice can lead to frequent cognitive errors in the periopera-
tive arena23,24, suggesting that the development of a real-time, tai-
lored feedback system to support intraoperative decision-making 
may be valuable. The development of automated feedback and 
alerting systems has been demonstrated to improve adherence 
to a number of treatment guidelines25–42. However, the impact of 
decision support systems appears to decay over time43–46, and 
improvements in process variables may not translate into improved 
patient outcomes47.
In the intensive care unit (ICU), the use of remote monitor-
ing to augment care, commonly referred to as “telemedi-
cine,” decreases ICU mortality and the length of ICU stay, and 
improves adherence to clinical practice guidelines48–52. While 
this type of clinical decision support has seen robust adoption 
in the critical care setting, its utilization in the intraoperative 
care of surgical patients is limited50. In light of the benefits that 
have been demonstrated from using telemedicine in the ICU 
setting, we believe that the implementation of such a system 
in the operating room has the potential to elevate the general 
safety and quality of perioperative care.
We have designed a multifaceted approach for the develop-
ment and institution of an Anesthesiology Control Tower 
(ACT) to provide real-time intraoperative telemedicine decision 
support. In the first component of our approach, we outlined 
a strategy of iterative usability testing and platform modifica-
tion that allowed us to develop a high-fidelity, user-centered 
system53. We intend to continue separate usability analyzes over 
the course of the pilot trial in order to evaluate the key usability 
elements of effectiveness, efficiency, and satisfaction54 in a more 
real-world setting. Because the impact of a clinical interven-
tion is dependent on the success of the process through which 
it is implemented55, we will also evaluate implementation out-
comes that are relevant to the use of the ACT in the periop-
erative setting56,57. In the second component of our approach, we 
will employ large-scale data analytics, integrating perioperative 
information in order to create forecasting algorithms for nega-
tive patient trajectories58. In the current manuscript, we describe 
the third element of our investigation: a pilot randomized con-
trolled trial that aims to demonstrate the superiority of the ACT 
in improving adherence to best care practices when compared 
to enhanced usual care.
Methods and analysis
Overview of research design
The ACTFAST-3 study is a pragmatic comparative effective-
ness trial that is taking place at an academic university-affiliated 
and adult tertiary care hospital in the United States that per-
forms over 19,000 surgeries a year. We plan to enroll approxi-
mately 12,000 patients over the study period, with approximately 
6,000 patients in the control arm and 6,000 patients in the inter-
vention arm (Figure 1). Patients will be included with a waiver 
of informed consent, as approved by the Human Research 
Protection Office (protocol number 201603038), as the risk 
associated with the ACT has been deemed to be minimal. 
Randomization will occur at the level of individual operating 
rooms on a daily basis.
The ACT will monitor all patients in both the control and inter-
vention operating rooms using information gathered from the 
electronic medical record (EMR) and from a customized ver-
sion of a perioperative monitoring and alerting program called 
AlertWatch® (Ann Arbor, MI). AlertWatch is an FDA-cleared 
(KI3O4OI) system that displays integrated patient informa-
tion and alerts clinicians to physiologic derangements. It was 
recently demonstrated that use of the AlertWatch software was 
associated with improvements in several process measures, 
although this did not translate into an effect on clinical out-
comes47. For the purposes of our intervention, the commercially 
available AlertWatch platform was heavily modified through 
usability testing53 to create a customized AlertWatch “Control 
Tower” mode that is only available within the ACT (Figure 2 
and Figure 3). The standard platform will remain available to 
all OR clinicians during this study. The ACT will provide clini-
cians in the intervention ORs with real-time feedback based on 
the available electronic resources, including AlertWatch Con-
trol Tower. Anesthesia providers in rooms assigned to the control 
group will also be monitored but will not receive decision 
support. Notably, the standard medical staffing models for 
providing an anesthetic will not be affected with this inter-
vention, as the ACT is designed to augment decision-making, 
rather than replace critical team members.
The primary outcome measures in the ACTFAST-3 pilot 
study are compliance with best care practices for intraopera-
tive temperature management and intraoperative blood glucose 
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Figure 1. Flow diagram of study population.
management (Table 1). We will also explore additional intra-
operative process measures in addition to surrogate outcomes 
(Table 2). The incidence of intraoperative hypotension and the 
incidence of postoperative renal dysfunction, atrial fibrillation, 
respiratory failure and delirium will be assessed via review of 
the EMR. Other postoperative complications, including intra-
operative awareness, surgical site infection, readmission, and 
death will be assessed via analysis of the existing Center for 
Clinical Excellence Registry, American College of Surgeons’ 
National Surgical Quality Improvement Program (NSQIP) data-
base, Society of Thoracic Surgery (STS) database, and Sys-
tematic Assessment and Targeted Improvement of Services 
Following Yearlong Surgical Outcomes Surveys (SATISFY-
SOS) database59. Outcomes related to the usability of the ACT 
intervention, including efficiency and efficacy of the software 
platform, will be obtained from AlertWatch data logs. These 
logs will also be used to obtain data related to the feasibility of 
implementing the pilot ACT. User satisfaction will be assessed 
through surveys administered to members of the anesthesia 
department.
Study population, randomization, and blinding
The trial will include all adult patients undergoing surgery at 
two campuses of an academic university-associated hospital, 
Barnes-Jewish Hospital (South Campus and Parkview Tower) 
(St. Louis, MI, USA), between 7:00 AM and 4:00 PM Mon-
day through Friday (Figure 1). This includes a total of 48 
operating room locations. The ACT will function on days when 
at least two anesthesia providers are available, one of whom must 
be an attending anesthesiologist. Patients undergoing surgical 
procedures with greater than 50% of the case length occurring 
outside of the ACT hours will be excluded from analysis. All 
patients younger than 18 will also be excluded from the study. 
Patients who undergo multiple surgeries in a single hospitaliza-
tion or who have a second surgical procedure within 30 days of 
their initial surgery will be analyzed according to their initial 
randomization assignment. Patients returning for a second sur-
gery more than 30 days after their initial surgical encounter will 
be considered as separate patients in the analysis. We will also 
obtain data from a group of historical control patients for 
the 6 months prior to the initiation of the ACTFAST-3 
study, as part of an analysis related to potential sources of bias and 
contamination.
A randomization algorithm integrated into the AlertWatch sys-
tem will direct patient group allocation on a daily basis. Due to 
the nature of the intervention in this study, clinicians work-
ing in the ACT and those randomized to receive support 
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Figure 2. Interface of the AlertWatch® Control Tower system. (A) AlertWatch® Control Tower Census View. This view shows summary 
information for operating rooms with ongoing procedures. Physiological alerts (e.g., low blood pressure) are shown as black or red squares, 
depending on the severity of the derangement, with red indicating a more severe abnormality. Checkmarks appear inside an operating room 
when an alert is triggered that has been classified as actionable and requires a resonse on the part of the clinicians in the Control Tower (see 
Figure 3). Control rooms are indicated with a “Do Not Contact” symbol. (B) AlertWatch® Control Tower Patient Display View. This deidentified 
intraoperative patient display demonstrates organ-specific information individualized to each patient. Colors outlining organs indicate normal 
(green), marginal (yellow) or abnormal function (red). Orange would indicate an organ system at risk due to pre-existing conditions. The left 
side of the display shows patient characteristics and the case information. Lab values, if available, are listed beneath the kidneys. Alerts 
generated by the AlertWatch® system are listed on the right-hand side of the display. Specific alerts, determined by the study team to be 
clinically significant and actionable, trigger a checkmark to appear at the bottom left of the screen. This informs the Anesthesiology Control 
Tower (ACT) clinician that an alert is present that must be addressed. Clicking on this checkmark allows clinicians in the ACT to review and 
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Figure 3. AlertWatch® Control Tower Case Review dialogue. Clinicians in the Anesthesiology Control Tower (ACT) use the Case Review 
window to address actionable Control Tower alerts, indicated by checkmarks on the Census View and the Patient Display. Within this Case 
Review window, clinicians document their assessment of the significant of each alert, what action they would recommend, and, in the case of 
intervention operating rooms (ORs), the reaction of the clinician in the OR to the ACT support.




Proportion of patients with 
final recorded intraoperative 
temperature greater than 36°C
Intraoperative blood 
glucose control
Proportion of cases with blood 
glucose 180 mg/dl upon arrival 
to the post-anesthesia recovery 
area
cannot be blinded to the intervention. Researchers responsi-
ble for extracting data during the course of the study will be 
blinded to group allocation at the time of extraction.
Primary intervention: ACT monitoring and decision support
A multidisciplinary team of clinicians in the ACT will 
remotely monitor all active operating rooms at the campus 
of interest. ACT clinicians will include attending anesthesi-
ologists, anesthesiology fellows, anesthesiology residents, and 
certified and student registered nurse anesthetists. Information 
will be obtained in near real-time from multiple complemen-
tary sources, including the AlertWatch Control Tower software 
(Figure 2) and the EMR. The clinicians in the ACT will use this 
information to communicate with OR clinicians to help maintain 
compliance with intraoperative best care practices and to assist 
with the detection and management of physiological derange-
ments32,60–63. These clinicians will evaluate all alerts generated 
by the AlertWatch Control Tower notification system (Figure 3), 
including alerts from both the intervention and the control oper-
ating rooms. For ORs allocated to the intervention arm, the 
ACT will deliver decision support to the primary personnel car-
ing for the patient via text message or telephone call. The cli-
nician receiving the alert will determine the applicability of 
the alert to the clinical situation and will choose whether to 
carry out any recommendations sent by the ACT. In patients 
with a persistent critical event, the ACT will offer real-time 
assistance with crisis resource management.
Operating rooms assigned to the control group will undergo 
the same monitoring and assessment by the ACT, but 
clinicians in these ORs will not receive any contact from the 
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obliged to contact a room assigned to the control group due 
to perceived potential for imminent and significant patient 
harm, they will be able to do so. Although we anticipate that 
this will be a rare occurrence, it will still be documented and 
reported as part of our study outcomes.
Data collection and outcome measures
Data collection for this study will utilize multiple sources to 
extract outcome measures64. All alert data generated by the Alert-
Watch Control Tower platform will be automatically logged 
to a secure database, including all responses by the providers in 
the ACT to individual alerts (Figure 3). Data from the periop-
erative period will be imported from Metavision® (iMDsoft, 
Wakefield, Massachusetts, USA), the anesthesiology infor-
mation management software system currently in use by the 
Department of Anesthesiology. In addition to capturing com-
prehensive intraoperative clinical data, Metavision® also stores 
preoperative information, such as patient characteristics, clinical 
and surgical history, comorbidities, and data from the imme-
diate post-operative period. Of note, during the anticipated 
duration of this trial, our hospital system will be transitioning 
to Epic Systems software (Verona, WI, USA) for both the hos-
pital electronic health record and the anesthesiology infor-
mation management software. Postoperative data for patient 
outcomes will be obtained from the inpatient EMR record 
system, and from clinical registries (SATISFY-SOS, NSQIP, STS).
Primary outcome measures
The primary outcome measures in the ACTFAST-3 study are 
compliance with recommendations for intraoperative tempera-
ture management and intraoperative blood glucose manage-
ment (Table 1). Data on primary outcomes measures will be 
recorded to an SQL server.
Secondary outcome measures
Secondary intraoperative outcomes will include several process, 
surrogate, clinical measures (Table 2). Intraoperative process 
outcomes will include blood pressure management, compli-
ance with recommendations for repeat dosing of antibiotics and 
for temperature monitoring, management of hyperglycemia, 
documentation of train of four monitoring following neuromus-
cular blockade, and adherence to strategies for intraoperative 
low tidal volume ventilation. Additionally, the impact of the 
ACT on volatile anesthetic usage will be assessed. We will also 
evaluate surrogate and clinical outcomes, specifically, the inci-
dence of postoperative acute renal failure, postoperative atrial 
fibrillation, postoperative respiratory failure, postoperative delir-
ium, intraoperative awareness, surgical site infection, 30-day 
Table 2. Secondary outcome measures and definitions.
Intraoperative process measures Outcomes
     Intraoperative blood pressure 
management
Mean duration of time spent with Mean Arterial Pressure <60 mmHg
    Temperature monitoring Proportion of procedures lasting greater than 1 hour with documented 
temperature 
    Antibiotic dosing Proportion of procedures with appropriate administration of repeat doses of 
antibiotics 
     Intraoperative blood glucose 
management
Proportion of cases with at least one dose of insulin administered for blood 
glucose greater than 180 mg/dl 
Intraoperative measurement of blood glucose in patients with type 1 
diabetes undergoing cases ≥1 hour in length and patients with type 2 
diabetes undergoing cases ≥2 hours in length
    Train of four documentation Proportion of cases with a train of four documented prior to extubation if a 
nondepolarizing neuromuscular blocking agent was administered 
    Ventilator management Proportion of cases with median tidal volume less than 10 ml/kg ideal body 
mass
    Volatile anesthetic utilization Mean and standard deviation of fresh gas flow rates for cases with volatile 
anesthetic use >80% of case duration
Postoperative surrogate measures Outcomes
    Postoperative acute renal failure Incidence of individual outcomes
    Postoperative atrial fibrillation
    Postoperative respiratory failure
    Postoperative delirium
    Intraoperative awareness
    Surgical site infection
    30-day readmission
    30-day mortality
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hospital readmission, and 30-day mortality. Data will be obtained 
from review of electronic health records and cross-referenc-
ing of patients in the ACTFAST study with other surgical data-
bases, as described above. We will also track the incidence of 
provider-reported intraoperative adverse events via a review of 
the departmental quality improvement database. Feasibility of 
implementing the ACT will be determined in part by examining 
the number of potentially staffed days versus the actual number 
of staffed days. Usability outcomes will include metrics such as 
the median number of alerts addressed by provider and across 
time.
Data analysis
Comparisons between groups will be with parametric and non- 
parametric statistical tests, as appropriate. Fisher’s exact or χ2 test 
will be used to evaluate primary outcome measures with regards 
to the following proportions: (i) the proportion of patients with 
a last-documented intraoperative temperature greater than 36 
degrees Celsius; and (ii) the proportion of patients arriving to the 
post-anesthesia care unit or ICU with a blood glucose greater than 
180 mg/dl. Contingency statistical tests will be used to compare 
occurrence of hypothermia and hyperglycemia between groups. 
Secondary outcomes will be compared between groups using 
χ2 or Fisher’s exact test for categorical outcomes, and two-sided 
t tests with unequal variances for comparison of means. By con-
vention, statistical significance will be based on a two-sided 
p value <0.05. All statistical testing will performed using SAS® 
version 9.4 (SAS Institute Inc., Cary, North Carolina, USA). 
The small subset of rare patients in the control group whose 
provider may be contacted by the ACT clinicians out of con-
cern for a significant patient safety event will be included in 
the control group in an intention-to-treat analysis. A sensitivity 
analysis will also be performed with inclusion of these patients 
in the intervention group. The frequency and rationale for 
contacting these rooms will be reported as part of our trial results.
Once the ACT intervention is executed, we anticipate several 
sources of contamination effect in the control group. There is 
a high likelihood of a robust Hawthorne effect due to OR clini-
cian awareness of the ACT monitoring65,66. Also, all clinicians 
in the OR will eventually be included in the intervention group, 
due to the unit of randomization, and will likely become aware 
of the best management practices of interest in this trial. There-
fore, even on days when they do not receive ACT support, 
clinicians may change their behavior, leading to overlapping 
improvements in both groups over the course of the study. Addi-
tionally, utilization of the AlertWatch software by clinicians in 
the ORs may increase over time. Learning effects might mani-
fest most strongly among clinicians who staff the ACT and are 
therefore sensitized to the interventions and outcomes in this 
study. In order to evaluate the extent of the contamination and 
Hawthorne effects, we will collect baseline data for the group 
of historical controls. For categorical variables, contamina-
tion will be analyzed using logistic regression with a three-level 
categorical variable representing group assignment (histori-
cal cohort, control group, or intervention group); continuous 
variables will be analyzed using ANCOVA or non-parametric 
ANCOVA67. Additionally, we will track which operating 
rooms utilize the AlertWatch system intraoperatively, and will 
plan to perform a subgroup analysis to assess the effect of the 
ACT in this subset of patients.
Within the AlertWatch system, all alerts that are generated are 
automatically logged to a secure database, as are all responses 
of the ACT clinicians to these alerts (Figure 3). We will 
analyze these logs to determine how clinicians in the ACT moni-
tor patients, address alerts, and interact with OR clinicians, and 
how OR clinicians respond to the ACT support. This data will 
allow us to explore aspects of the real-world usability of the 
ACT intervention related to efficiency and effectiveness, and 
will complement information gathered from qualitative usability 
surveys administered to department members.
Sample size and power analysis
In this study, we plan to enroll a convenience sample of 
12,000 patients over the course of the study period, based 
on the staffing available for the ACT and the usual daily 
surgical volume of approximately 125 cases. Power analysis 
was based on the two primary outcomes defined for this study, 
with the following assumptions:
 i) Regarding the core-temperature outcome, we conserva-
tively assumed that only 80% of Barnes-Jewish Hospital 
patients have their core temperature recorded during sur-
gery. Among patients with their temperature documented, 
the target for this outcome was that the ACT intervention 
will increase the proportion of patients whose final recorded 
intraoperative temperature is above 36°C from 60% to 
95%. For this calculation we assumed a standard deviation 
of core temperature of 0.9 degrees Celsius for both groups, 
based on an unpublished EMR audit.
 ii) Regarding the primary outcome of glucose control, we 
assumed that the prevalence of diabetes mellitus among 
Barnes-Jewish Hospital surgical patients is about 20%, 
based on our EMR data over the past 5 years. Based on 
the same data, we also assumed that currently 60% of our 
diabetic patients reach a blood glucose >180 mg/dl at any 
point during surgery. Our goal was that the ACT interven-
tion will reduce the proportion of patients arriving to the 
Post Anesthesia Care Unit (PACU) with a blood glucose 
value greater than 180 mg/dl from 60% to 40%.
A statistical power calculation based on the above assumptions 
was performed for each of the two primary study outcomes to 
determine whether the sample size (N=12,000) allocated for 
this study is adequate. The effective sample size for the study 
was defined as the largest sample needed to achieve any of the 
two stated outcomes. We mainly powered all targeted outcomes 
to detect a difference in proportions (adjusted for contamina-
tion between the two study groups) in a completely balanced 
clustered-randomized design study (24 operating rooms in each 
group) using two-sided Z-test statistics. We also assumed a mini-
mum to 90% power, a significance level of 0.05, an intracluster 
correlation coefficient (ICC) varying between 0.01 and 0.05 by a 
small increment of 0.005, and a coefficient of variation of cluster 
sizes of 0.50. Table 3 shows the required sample per operating 
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room as well as the overall sample needed to achieve the 
study targeted outcomes. The largest sample was required for 
the proportion of patients whose last recorded intraoperative 
temperature is equal to or greater than 36°C (N=11,472). This value 
was sufficient for the other primary outcome.
Substudy in educational curriculum
While the primary goal of the ACTFAST-3 study is to evalu-
ate the impact of the ACT on patient care and outcomes, the 
structure and environment of the ACT has allowed for the crea-
tion of a novel curriculum in perioperative medicine. The 
current educational paradigm for anesthesiology residents pri-
marily focuses on the management of individual patients in the 
perioperative setting. However, the substantial increase in require-
ments for surgical procedures, a projected shortage of anesthesi-
ologists, and financial constraints in healthcare suggest that it 
will eventually be infeasible for anesthesiologists to provide the 
level of supervision that is currently standard in the United States 
(e.g. one anesthesiologist for every one to four ORs)68. There is 
currently little emphasis in anesthesiology education on process 
management and multitasking and caring for multiple patients 
in a complex care environment. With the support of the resi-
dency program director and departmental chair, we have revised 
the residency curriculum at our institute to allow each anesthe-
sia resident to spend 2 weeks in the ACT during their final 
year of residency. We plan to implement an educational cur-
riculum in perioperative telemedicine, focusing on the utiliza-
tion of healthcare system resources to optimize intraoperative 
management, improve quality, and provide oversight of multiple 
patients undergoing complex surgical procedures.
Adverse events and safety monitoring
We do not anticipate the occurrence of significant adverse 
events during this study. However, the primary investigator and 
the study team will review any adverse events identified by the 
departmental quality improvement program as potentially attrib-
utable to the ACT. The occurrence of any significant adverse 
events will be reported to the HRPO, and the study team and 
HRPO would decide together whether to halt the trial. No formal 
data-monitoring committee will used. There will be no audit of 
trial conduct during the investigation, although data recorded 
via the AlertWatch system will be reviewed and analyzed to 
determine appropriate group allocation and inclusion in the 
final analysis. No interim data analysis is planned for this 
pilot trial unless unanticipated safety issues are identified. 
There are no provisions for post-trial care or compensation 
to patients enrolled as part of this trial, as the intervention in 
the ACTFAST-3 trial involves only the addition of real-time 
decision-support tools and does not change existing anesthesia 
care models.
Data management
The risk of breach of confidentiality will be minimized. The 
data necessary for the completion of the trial will be pro-
tected by passwords and is contained in applications that are 
compliant for protected healthcare information (PHI). AlertWatch 
meets this same standard of protection. Individual clinical alerts 
and the ACT evaluation of these alert will be documented using 
an electronic data capture tool in the AlertWatch system. Out-
comes data will be stored on one of two Washington University 
Department of Anesthesiology servers (a SQL server or a Win-
dows file server). Only trained employees of the Department of 
Anesthesiology or Barnes Jewish Healthcare are granted access to 
resources on this network. Access to the contents of this study will 
be further restricted to approved personnel only, using server-level 
permission access (for the SQL server), or Windows folder per-
mission settings (for the file server). It is a strict policy that PHI 
cannot be saved or reviewed outside of this protected environ-
ment. Whenever possible, extracts for this project will avoid 
the use of this information. Data extracts can be reconnected 
to PHI using a special, non-PHI primary key, which this group 
has successfully used with previous studies.
Strengths and limitations
The ACTFAST pilot study has important strengths. It is a ran-
domized clinical trial conducted in a high volume, real world 
clinical setting and can be conducted efficiently, as many com-
ponents of the proposed study are incorporated into existing 
infrastructures and processes at Washington University. This 
includes access to existing information technology resources and 
to established and ongoing registries (SATISFY-SOS, NSQIP 
and STS). The data required for analysis of the primary out-
come measures are routinely recorded on every patient undergo-
ing surgery at our institution, and the databases used for analysis 
of secondary surrogate and clinical outcomes also all have high 
levels of data fidelity.













50% 24(239) 24 
(239)
95% 90% 0.0375 11,472
Post- operative 
Blood Glucose ≥ 
180 mg/dL
60% 24(59) 24 
(59)
40% 50% 0.03 2,832
†See Table 1 for full explanation of outcomes.
*High contamination effects were set to reach 67% as 2 out of 3 physicians will participate in the ACT.
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Randomization of anesthesiology care teams can be eas-
ily implemented, and the process for providing feedback alerts 
does not require any advanced preparation on the part of clini-
cians working in the OR. These clinicians will participate in 
the ACTFAST trial in the course of their routine clinical work, 
and the impact on overall workflow and workload will be mini-
mized through the testing in our first phase of the study53. We 
anticipate that it will be feasible to staff the ACT during the pilot 
RCT. The feasibility is enhanced by participation of a highly 
committed cadre of attending anesthesiologists and all of 
the residents in the anesthesiology department, as well as an 
experienced team of investigators that has established a track 
record of collaboration and completion of major clinical trials.
The following limitations should be considered. The Alert-
Watch software is currently available on all computers in 
the OR, and in-room provider utilization of AlertWatch may 
increase over the course of the study. In response, we plan to 
conduct a subgroup analysis with user log-in data to ascertain 
the impact of in-room software utilization, defined as docu-
mentation of intraoperative provider log-in to the AlertWatch 
system. Also, the ACTFAST study will be vulnerable both to 
Hawthorne and contamination effects. While we do not think 
that these effects can be eliminated, we have considered 
how best to account for them in the analyses. An important 
constraint and possible source of bias will be that it will not be 
possible to ensure blinding of OR clinicians as any communica-
tion from the ACT will inform them that their operating room 
is in the intervention group on that day69. However, clinicians 
outside of the OR, and the researchers responsible for extracting 
data, will be blinded to group assignment.
Another potential source of bias involves the existing surgi-
cal databases that will be used during analysis (i.e. STS, NSQIP, 
SATISFY-SOS). These registries themselves may be biased 
according to which patients choose to participate, with indi-
vidual patients’ outcomes impacting their willingness or ability 
to provide reliable information, and which patients are contacta-
ble. We have been attempting to mitigate this source of bias by 
employing three modalities (e-mail, telephone and mail) to reach 
patients postoperatively in one such study59. Overall, the regis-
tries have impressive response rates, and there does not appear 
to be systematic bias in any of these registries based on baseline 
patient characteristics. Therefore, we expect our data sources 
to be robust, with minimal deficiencies.
Ethics and dissemination
This study was approved by the HRPO at Washington Univer-
sity (St. Louis, MI, USA, protocol number 201603038). This 
protocol is written in compliance with the Standard Protocol 
Items: Recommendations for Interventional Trials (SPIRIT) 
checklist with consideration of the Consolidated Standards of 
Reporting Trials (CONSORT) guidelines70,71.
If the results of the pilot ACTFAST-3 trial show benefit, the 
pilot study will likely be replicated as a larger, multicenter study 
for further validation that this intervention remains beneficial 
and that it is feasible to institute at other centers. We also antici-
pate the expansion of the ACT into the surrounding healthcare 
facilities within our hospital system. Larger trials could focus 
on expanded clinical and patient-reported outcomes (e.g. death, 
renal failure, delirium, duration of mechanical ventilation, inten-
sive care length of stay, post-discharge disposition, postoperative 
falls, return to work, disability-free survival). The ACT infra-
structure could also be used to explore current controversies 
in perioperative care by testing candidate experimental 
interventions (e.g., fluid management strategies, blood trans-
fusion triggers). We envision that national implementation 
of the ACT concept would occur, which would be 
comparable to the path that similar programs for intensive care 
units have followed.
Any significant changes to the protocol or the analysis plan 
during the trial will be communicated directly to the Washing-
ton University HRPO, as well as via update of the ACTFAST-3 
registration at clinicaltrials.gov (ClinicalTrials.gov Identifier: 
NCT02830126). We also plan to publish any modifications 
made to this protocol during dissemination of the results of the 
trial. Authorship for the final trial data will be determined in 
accordance with International Committee of Medical Journal 
Editors (ICMJE) guidelines.
Data sharing
Data from the ACTFAST-3 trial will be made available for analy-
sis in compliance with the recommendations of the ICMJE72. For 
this study, individual participant data that underlie the results of 
the trial will be made available after appropriate deidentifica-
tion, along with the study protocol and statistical analysis plan. 
We plan to make this information accessible to researchers who 
provide a methodologically appropriate proposal for the purpose 
of achieving the aims of that proposal. Data will be available 
beginning 9 months and ending 36 months following trial publi-
cation at a third-party website. Data requestors will need to sign 
a data access agreement to gain access to trial data. Proposals 
should be directed to avidanm@wustl.edu.
Conclusions
Despite aggressive efforts aimed to improve the quality of peri-
operative care, the risk of morbidity and mortality following a 
major surgical procedure remains substantial. In this protocol, 
we describe a pilot pragmatic, randomized, controlled trial in 
intraoperative telemedicine that examines the ability of a novel 
system of real-time feedback to improve adherence to periopera-
tive best care practices. We hypothesize that the implementation 
of the ACT will be feasible and that it will increase clinician 
compliance with clinical practice standards. The development of 
the ACT, as described in this protocol, will also lay the ground-
work for a subsequent large randomized controlled trial exam-
ining the utility of the ACT in improving patient outcomes 
following surgical procedures.
The findings from the trial will be disseminated in the form 
of posters and oral presentations at scientific conferences, as 
well as publications in peer-reviewed journals. Updates and 
results of the study will be available at https://clinicaltrials.gov/ 
ct2/show/NCT02830126.
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